Takamura S, et al. - The efficacy and safety of apremilast combined with biologics were ascertained in 14 patients with psoriasis showing biologic fatigue at a single hospital. The mean Psoriasis Area and Severity Index (PASI) score was 3.2 ± 0.4 before the addition of apremilast. At week 24 following the addition of apremilast, researchers observed a decrease in the mean PASI score to 1.6 ± 0.3 and identified 75% and 50% reduction in PASI score in four (29%) and seven (50%) patients, respectively. Outcomes suggest that for managing patients with psoriasis showing biologic fatigue, the combination treatment of apremilast and biologics could be a safe, effective option.